AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23681030
Drug: Intravenous dexamethasone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexamethasone, 8 mg
Trial: 21685111
Drug: Intranasal DEX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal DEX 1 µg kg(‐1) (Group D)
Trial: 19214556
Drug: Beta-alanine supplementation
RxNorm normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine supplementation (6.4 g day(-1))
Trial: 11471851
Drug: Proprietary omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proprietary omeprazole (20 ‐ 40 mg/day depending on age) + metronidazole (30 ‐ 40 mg/kg per day) + amoxycillin (750 mg/day)
Trial: 11471851
Drug: Generic omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic omeprazole (20 ‐ 40 mg/day) + metronidazole (30 ‐ 40 mg/kg per day) + amoxycillin (750 mg/day)
Trial: 26395410
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment for acetabular deformities
Trial: 21676892
Drug: 0.5% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ropivacaine mixed with dexamethasone 8 mg
Trial: 21676892
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine mixed with dexamethasone 8 mg
Trial: 19706108
Drug: 308-nm excimer
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 308-nm excimer laser therapy with topical 1% pimecrolimus cream twice daily (group A)
Trial: 19706108
Drug: Excimer laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excimer laser therapy twice per week (group B)
Trial: 11306521
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg/d (n=35)
Trial: 7745014
Drug: 75 IU
RxNorm normalized name: Follitropin Beta 75 IU/0.5 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 IU human urinary FSH (uFSH) administered subcutaneously (sc)
Trial: 31628490
Drug: Romosozumab 210
RxNorm normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romosozumab 210 mg monthly followed by placebo (n=19)
Trial: 25661462
Drug: Dry needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry needling treatment of a single active MTrP
Trial: 23382539
Drug: Identically dosed
RxNorm normalized name: HUMAN PLACENTA-DERIVED ADHERENT (PDA) CELLS THAT ARE CULTURE-EXPANDED, UNDIFFERENTIATED MESENCHYMAL-LIKE CELLS DERIVED FROM FULL-TERM PLACENTAL TISSUE. CELLULAR IDENTITY: MESENCHYMAL-LIKE STROMAL CELL: CD34-, CD10+, CD105+, AND CD200+.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identically dosed agents in separate pills taken at different time points during the day
Trial: 17879926
Drug: Simplification strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simplification strategy using a boosted protease inhibitor (PI) alone
Trial: 10469040
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg of oral terfenadine
Trial: 10469040
Drug: 120 microg
RxNorm normalized name: Betamethasone 120 microgram/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 microg of inhaled ipratropium bromide
Trial: 30784555
Drug: Prasugrel (3·75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (3·75 mg/day)
Trial: 9679818
Drug: Thymoglobulin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoglobulin (1.5 mg/kg/day for 7-14 days)
Trial: 9679818
Drug: Atgam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atgam (15 mg/kg/day for 7-14 days)
Trial: 2566160
Drug: Broxaterol (new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broxaterol (new beta 2-agonist)
Trial: 21249218
Drug: Sodium nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium nitrite infusion
Trial: 9266780
Drug: Warfarin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin therapy (INR 2.7 +/‐ 1.3)
Trial: 9266780
Drug: Low-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity warfarin (INR 1.3 +/‐ 0.08)
Trial: 9266780
Drug: Moderate-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-intensity warfarin (INR 2.3 +/‐ 1.1)
Trial: 2228932
Drug: Active medication
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active medication groups (Alprazolam and Imipramine combined)
Trial: 15355358
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light treatment
Trial: 26220257
Drug: Foot reflexology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot reflexology treatment for 20-30 minutes before vaccination
Trial: 23730858
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no reflexology treatment)
Trial: 24693675
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor (Rabeprazole 20 mg once a day)
Trial: 24693675
Drug: Histamine H2
RxNorm normalized name: Histamine H2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine H2 receptor antagonist (Famotidine 20 mg twice a day)
Trial: 21205246
Drug: Maximum conservative
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum conservative treatment alone
Trial: 19663519
Drug: TRC4186 250-2500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRC4186 250-2500 mg single dose
Trial: 19663519
Drug: TRC4186 500-2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRC4186 500-2000 mg multiple doses (twice daily for 6 days)
Trial: 19663519
Drug: TRC4186 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRC4186 500 mg (fasted) vs 500 mg (fed)
Trial: 19663519
Drug: TRC4186 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRC4186 500 mg followed by 1000 mg after 7-day washout in elderly subjects
Trial: 9429043
Drug: 0.05 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg.kg‐1 rocuronium, 3 min before 2 mg.kg‐1 succinylcholine (ROC‐3 min)
Trial: 9429043
Drug: 0.05 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg.kg‐1 rocuronium, 1.5 min before 2 mg.kg‐1 succinylcholine (ROC‐1.5 min)
Trial: 23080351
Drug: Liposome bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposome bupivacaine 266 mg
Trial: 11738299
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) users
Trial: 9033324
Drug: Heparin loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin loading dose of 300 U/kg followed by 3 U/mL of heparin in the prime (high-dose group)
Trial: 8285609
Drug: Rufloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rufloxacin 400 mg on day 1 and 200 mg daily for 9 days (n = 64)
Trial: 8285609
Drug: Rufloxacin 300
RxNorm normalized name: ofloxacin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rufloxacin 300 mg on day 1 and 150 mg daily for 9 days (n = 63)
Trial: 8285609
Drug: Amoxicillin 500
RxNorm normalized name: amoxicillin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 500 mg three times a day for 10 days (n = 65)
Trial: 17254453
Drug: IVIG 1
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 1 g/kg
Trial: 17254453
Drug: IVIG 2
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 2 g/kg
Trial: 9625835
Drug: Serum p53
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum p53 antibodies positive patients (33 out of 57)
Trial: 8003109
Drug: Glucose and
RxNorm normalized name: Glucose and treacle only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose and xylitol mixture (1:1; 2 mg/kg BW/min)
Trial: 8003109
Drug: Glucose-containing electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-containing electrolyte solution (0.8 mg/kg BW/min)
Trial: 8003109
Drug: Glucose-xylitol mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-xylitol mixture (4 mg/kg BW/min)
Trial: 18544005
Drug: Tetrabenazine treatment
RxNorm normalized name: Tetrabenazine
DrugBank: Tetrabenazine (DB04844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetrabenazine treatment for 2 years
Trial: 18544005
Drug: Tetrabenazine treatment
RxNorm normalized name: Tetrabenazine
DrugBank: Tetrabenazine (DB04844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetrabenazine treatment for a mean duration of 19 months
Trial: 1725540
Drug: nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine 10 mg t.i.d.
Trial: 1725540
Drug: nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine 20 mg t.i.d.
Trial: 1725540
Drug: diltiazem 60
RxNorm normalized name: DILTIAZEM 60MG 12HR CAP,SA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diltiazem 60 mg t.i.d.
Trial: 1725540
Drug: diltiazem 120
RxNorm normalized name: diltiazem 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diltiazem 120 mg t.i.d.
Trial: 1725540
Drug: verapamil 40
RxNorm normalized name: verapamil 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil 40 mg q.i.d.
Trial: 6596060
Drug: Intracoronary streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary streptokinase therapy
Trial: 10497668
Drug: Minolest (16.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minolest (16.5 g/day)
Trial: 7590572
Drug: Effervescent tablet
RxNorm normalized name: Pain Relief Effervescent Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent tablet of sucralfate (2.0 g twice daily)
Trial: 7590572
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (effervescent and granular)
Trial: 20215608
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine (control)
Trial: 10367588
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of partial agonists with ICI 118,551
Trial: 3896659
Drug: Slow-release indomethacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release indomethacin (50 mg)
Trial: 6510016
Drug: Diflunisal (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal (250 mg)
Trial: 17584562
Drug: Nebivolol 10
RxNorm normalized name: nebivolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 10 mg
Trial: 25139609
Drug: Subcutaneous continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous continuous glucose monitoring (CGM)
Trial: 22021700
Drug: Citalopram (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (2 ml intravenously)
Trial: 22021700
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 ml of 0.9% NaCl intravenously)
Trial: 19692881
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (100 mL 0.9% NaCl infused intravenously)
Trial: 11103054
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa high-dose (40,000 U)
Trial: 9263613
Drug: Ipriflavone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipriflavone (200 mg T.I.D. at meals) plus 1 g oral calcium daily
Trial: 9263613
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus 1 g oral calcium daily
Trial: 8518909
Drug: Division of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Division of the superior rectal artery
Trial: 24525635
Drug: Baclofen (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (40 mg/d) + Citalopram (20 to 60 mg/d)
Trial: 24525635
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 to 60 mg/d) + Placebo
Trial: 23298508
Drug: Serenoa repens
RxNorm normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serenoa repens 320 mg every day for 24 months
Trial: 23298508
Drug: Finasteride 1
RxNorm normalized name: finasteride 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 1 mg every day for 24 months
Trial: 19478343
Drug: Rhodiola rosea
RxNorm normalized name: RHODIOLA ROSEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhodiola rosea extract, 100 mg twice daily for 4 weeks
Trial: 15904630
Drug: Omapatrilat 80
RxNorm normalized name: OMAPATRILAT
DrugBank: Omapatrilat (DB00886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omapatrilat 80 mg/day
Trial: 12683707
Drug: Domiciliary pulmonary
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domiciliary pulmonary rehabilitation program (walking, breathing exercises, postural drainage, controlled coughing, lifestyle changes) for 30 minutes twice daily for four weeks
Trial: 7557824
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth (CBS) 240 mg bid for 4-8 weeks, followed by placebo maintenance treatment
Trial: 7557824
Drug: Famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg nocte for 4-8 weeks, followed by 20 mg for 12 months after healing
Trial: 16930802
Drug: L-Theanine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Theanine at the start of the experimental procedure
Trial: 16930802
Drug: L-Theanine midway
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Theanine midway through the experimental procedure
Trial: 23229858
Drug: Cilobradine 0.25-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilobradine 0.25-5 mg doses
Trial: 18763638
Drug: Grape procyanidins
RxNorm normalized name: procyanidin A2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape procyanidins (GPC) 100 mg/day for 60 days
Trial: 18763638
Drug: Starch capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch capsule (control)
Trial: 17182445
Drug: Cocaine pharmacotherapy
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine pharmacotherapy
Trial: 27741192
Drug: Intra-fetal digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-fetal digoxin (1.0 mg)
Trial: 27741192
Drug: Intra-amniotic digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-amniotic digoxin (1.0 mg)
Trial: 16025963
Drug: Xinfang rhinitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinfang rhinitis capsule (Control)
Trial: 1987744
Drug: Multiagent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiagent chemotherapy regimen of CAP
Trial: 6398833
Drug: Oxamniquine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxamniquine (15 mg/kg)
Trial: 31752815
Drug: standard group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard group therapy
Trial: 23317480
Drug: Elaborated VF
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elaborated VF (VF plus cognitive preparation and cognitive review)
Trial: 16187232
Drug: Immunotherapy (aPBSC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (aPBSC transplant with IL-2 incubation for 24 hours followed by parenteral IL-2 for 5 days, then 2 days of rest for 4 weeks)
Trial: 8652333
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg on the evening before and 40 mg on the morning of surgery
Trial: 8652333
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg on the evening before surgery and 2 h before anaesthesia
Trial: 28982956
Drug: Topical medication
RxNorm normalized name: Procto-Med Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical medication without laser
Trial: 18181978
Drug: Desloratadine 5
RxNorm normalized name: desloratadine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine 5 mg daily for 42 days
Trial: 12791570
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of the NMDA receptor antagonist memantine
Trial: 6347380
Drug: Netilmicin, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netilmicin, 2 mg/kg every eight hours for a minimum of 72 hours
Trial: 6347380
Drug: Tobramycin, 1
RxNorm normalized name: Tobramycin, 10 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin, 1 mg/kg every eight hours for a minimum of 72 hours
Trial: 22816213
Drug: L2-3 spinal
RxNorm normalized name: bovine spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L2-3 spinal anesthesia with 15 mg 0.5% isobaric bupivacaine
Trial: 22816213
Drug: L3-4 spinal
RxNorm normalized name: bovine spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L3-4 spinal anesthesia with 15 mg 0.5% isobaric bupivacaine
Trial: 12381637
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day amiloride (one month)
Trial: 2180493
Drug: Chlorambucil (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorambucil (0.1 mg/kg/d)
Trial: 25325454
Drug: 17β estradiol
RxNorm normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17β estradiol 0.5 mg/day
Trial: 25325454
Drug: venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: venlafaxine XR 75 mg/day
Trial: 21542914
Drug: Hip school
RxNorm normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hip school + Manual therapy (group B) - 6 weeks, 5 sessions of hip school + manual therapy twice a week
Trial: 7942533
Drug: 81 mg
RxNorm normalized name: aspirin 81 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg aspirin
Trial: 7942533
Drug: 162 mg
RxNorm normalized name: aspirin 162 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 162 mg aspirin
Trial: 11475709
Drug: Philips/Jordan electric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Philips/Jordan electric toothbrush with CPS set at various levels (150-420 g)
Trial: 2196627
Drug: Clomipramine (CMI)
DrugBank: Clomipramine (DB01242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomipramine (CMI) up to 300 mg daily for up to 10 weeks
Trial: 28220020
Drug: CAP (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAP (1,000 mg/m2 orally twice daily, days 1-14)
Trial: 12970273
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg, three times daily)
Trial: 12970273
Drug: Dianette (ethinyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dianette (ethinyl estradiol, 35 micro g; cyproterone acetate, 2 mg)
Trial: 8909666
Drug: H1 receptor
RxNorm normalized name: Histamine H1 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1 receptor blocker (terfenadine 60 mg)
Trial: 8909666
Drug: H2 receptor
RxNorm normalized name: Histamine H2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 receptor blocker (ranitidine 300 mg)
Trial: 8909666
Drug: H1 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1 and H2 receptor blockers (terfenadine 60 mg and ranitidine 300 mg)
Trial: 6222473
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g mezlocillin given during induction of anesthesia
Trial: 3990155
Drug: Phenobarbitone treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbitone treatment
Trial: 24405796
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine intracervical injection
Trial: 24405796
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 2% lidocaine gel
Trial: 22863639
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no cream or oil)
Trial: 12881822
Drug: Transcutaneous electric
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electric nerve stimulation (TENS) therapy
Trial: 8692532
Drug: No G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No G-CSF (no cytopenia)
Trial: 8692532
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no G-CSF despite insufficient leukocyte recovery)
Trial: 1656181
Drug: rHu‐EPO treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHu‐EPO treatment (3 X 80 IE/kg/week for six months)